Zobrazeno 1 - 10
of 124
pro vyhledávání: '"Yong Wha, Moon"'
Autor:
Nar Bahadur Katuwal, Min Sil Kang, Mithun Ghosh, Sa Deok Hong, Yeong Gyu Jeong, Seong Min Park, Seul-Gi Kim, Joohyuk Sohn, Tae Hoen Kim, Yong Wha Moon
Publikováno v:
Journal of Experimental & Clinical Cancer Research, Vol 42, Iss 1, Pp 1-21 (2023)
Abstract Background Breast cancer is the global leading cancer burden in women and the hormone receptor-positive (HR+) subtype is a major part of breast cancer. Though cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors are highly effective therapy f
Externí odkaz:
https://doaj.org/article/d6b66fd44da1438f93bf7bcc8096c727
Autor:
Yong Wha Moon1, Seung Ki Kim2, Keun Seok Lee3, Moon Hee Lee4, Yeon Hee Park5, Kyong Hwa Park6, Gun Min Kim7, Seungtaek Lim8, Seung Ah Lee2, Jae Duk Choi9, Eunhye Baek9, Hyesun Han9, Seungjae Baek9, Seock-Ah Im10 moisa@snu.ac.kr
Publikováno v:
Cancer Research & Treatment. Jul2023, Vol. 55 Issue 3, p766-777. 12p.
Autor:
Daun Jung, Young Seok Baek, In Jee Lee, Ki Yeon Kim, Heejoo Jang, Sohyun Hwang, Jieun Jung, Yong-wha Moon, Kyung-Soon Park, Yong-Soo Choi, Hee Jung An
Publikováno v:
Journal of Experimental & Clinical Cancer Research, Vol 40, Iss 1, Pp 1-14 (2021)
Abstract Background Recently, allogeneic natural killer (NK) cells have gained considerable attention as promising immunotherapeutic tools due to their unique biological functions and characteristics. Although many NK expansion strategies have been r
Externí odkaz:
https://doaj.org/article/0012dff126bd4b0a93bde27377c06b52
Autor:
Patrick Wayne Cobb, Yong Wha Moon, Klára Mezei, István Láng, Gajanan Bhat, Shanta Chawla, Steven J. Hasal, Lee S. Schwartzberg
Publikováno v:
Cancer Medicine, Vol 9, Iss 17, Pp 6234-6243 (2020)
Abstract Eflapegrastim (Rolontis®) is a novel, long‐acting hematopoietic growth factor consisting of a recombinant human granulocyte‐colony stimulating factor (rhG‐CSF) analog conjugated to a human IgG4 Fc fragment via a short polyethylene gly
Externí odkaz:
https://doaj.org/article/88a9560255c6486fb96283aa83575700
Autor:
Sung-Bae Kim, Jae Hong Seo, Jin-Hee Ahn, Tae-Yong Kim, Seok Yun Kang, Joohyuk Sohn, Yaewon Yang, Kyong Hwa Park, Yong Wha Moon, Seungtaek Lim, Myoung Joo Kang, Koung Eun Yoon, Hyun Ju Cho, Keun Seok Lee
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 13 (2021)
Background: Standard intravenous (IV) paclitaxel is associated with hypersensitivity/toxicity. Alternative IV formulations have improved tolerability but still require frequent hospital visits and IV infusion. DHP107 is a novel oral formulation of pa
Externí odkaz:
https://doaj.org/article/d67c1aea2ed64ac8bad679b39788b980
Autor:
Yong Wha Moon, Sungkyu Lee
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
Externí odkaz:
https://doaj.org/article/b1abc7e931c6482a95b2f99e82219f9f
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-4 (2019)
Externí odkaz:
https://doaj.org/article/8e92a751010b4602939b6d176af1819b
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-12 (2019)
Abstract Background Natural killer (NK) cells are an emerging new tool for cancer immunotherapy. To develop NK cell therapeutics from peripheral blood mononuclear cells (PBMCs) of healthy donors, substantial expansion of primary NK cells is necessary
Externí odkaz:
https://doaj.org/article/13c989e71e24425db2a67f7aab625816
Autor:
Min Hwan Kim, Yohan Yang, Eunyoung Kim, Yong Wha Moon, Gun Min Kim, Seul-Gi Kim, Yee Soo Chae, Jieun Lee, Jae Ho Jeong, Kyung-Hun Lee, Han Jo Kim, Joo Young Jung, Su-Jin Koh, Kyoung Eun Lee, Hee-Jun Kim, Kyong Hwa Park, Seungtaek Lim, Yeon Hee Park, Sangwoo Kim, Joo Hyuk Sohn
Publikováno v:
Cancer Research. 83:P5-14
Background The hormone receptor (HR)-positive metastatic breast cancer (MBC) patients show a diverse range of tumor mutational burden (TMB), but its biological and clinical implication has been largely unrevealed. Here we report genomic landscape of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::80f8f12ee8026f59f0a964dd9dca0f35
https://doi.org/10.1158/1538-7445.sabcs22-p5-14-04
https://doi.org/10.1158/1538-7445.sabcs22-p5-14-04
Publikováno v:
Cancer Research. 83:P2-26
Background: The PI3K inhibition has been an appealing approach for anticancer therapy due to its crucial role in cell growth, proliferation, and survival in various cancers. Emerging data suggest the PI3K pathway is also involved in DNA replication a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::541a919fa58ffd23f5558dfa49bc7566
https://doi.org/10.1158/1538-7445.sabcs22-p2-26-09
https://doi.org/10.1158/1538-7445.sabcs22-p2-26-09